FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080963620> ?p ?o ?g. }

• W2080963620 endingPage "354" @default.
• W2080963620 startingPage "350" @default.
• W2080963620 abstract "While high-dose bolus inpatient interleukin-2 is generally given on 8-week cycles, continuous infusion interleukin-2 could potentially allow for more rapidly repeated cycles. Fourteen (14) patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, having either kidney cancer (6) or melanoma (8), have been treated with continuous infusion (CIV) interleukin-2 (IL-2) 18 MIU/m2/24 hours for 72 hours. Cycles were repeated every 3 weeks up to 4 cycles, then every 3–4 weeks for 2 cycles, then every 6–8 weeks, until progression or intolerable toxicity. All patients received famotidine 20 mg intravenously (i.v.) twice per day during the 72-hour infusions. Patient characteristics included a median ECOG performance status of 1; median age = 63 (range: 25–79); most common metastatic sites: lung (9), bone (5), lymph nodes (5), and the liver (3). No patients with metastatic kidney cancer underwent a nephrectomy prior to interleukin-2. Median number of cycles received = 5 (1–9). No patients required Intensive Care Unit (ICU) admission. There have been no treatment-related deaths. Most common toxicities have been rigors, fever, nausea/emesis, and the reversible elevation of creatinine. One complete response and three partial responses (67% response rate; 95% confidence interval: 30%–90%) have been seen in kidney cancer, and two partial responses (25% response rate; 95% confidence interval: 7%–60%) have occurred in melanoma. Median survival has not been reached at >9+ months. Responding sites include the liver, bone, lung, lymph node and subcutaneous sites. Inpatient 72-hour continuous infusion interleukin-2 at this dose and schedule is well tolerated by patients with an ECOG performance status of 0 or 1 and has activity in kidney cancer and melanoma." @default.
• W2080963620 created "2016-06-24" @default.
• W2080963620 creator A5007449877 @default.
• W2080963620 creator A5012296345 @default.
• W2080963620 creator A5012408300 @default.
• W2080963620 creator A5013556625 @default.
• W2080963620 creator A5016011073 @default.
• W2080963620 creator A5059081727 @default.
• W2080963620 date "2004-06-01" @default.
• W2080963620 modified "2023-09-26" @default.
• W2080963620 title "Repeated Cycles with 72-Hour Continuous Infusion Interleukin-2 in Kidney Cancer and Melanoma" @default.
• W2080963620 cites W1904436785 @default.
• W2080963620 cites W1963717447 @default.
• W2080963620 cites W2013411992 @default.
• W2080963620 cites W2047786043 @default.
• W2080963620 cites W2062268724 @default.
• W2080963620 cites W2065393730 @default.
• W2080963620 cites W2092390196 @default.
• W2080963620 cites W2100921929 @default.
• W2080963620 cites W2102016301 @default.
• W2080963620 cites W2158391991 @default.
• W2080963620 cites W2171939187 @default.
• W2080963620 cites W2222964685 @default.
• W2080963620 cites W2251044420 @default.
• W2080963620 cites W2270697554 @default.
• W2080963620 cites W2271209459 @default.
• W2080963620 cites W2411162430 @default.
• W2080963620 cites W44017933 @default.
• W2080963620 doi "https://doi.org/10.1089/1084978041424972" @default.
• W2080963620 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15285881" @default.
• W2080963620 hasPublicationYear "2004" @default.
• W2080963620 type Work @default.
• W2080963620 sameAs 2080963620 @default.
• W2080963620 citedByCount "18" @default.
• W2080963620 countsByYear W20809636202012 @default.
• W2080963620 countsByYear W20809636202013 @default.
• W2080963620 countsByYear W20809636202014 @default.
• W2080963620 countsByYear W20809636202018 @default.
• W2080963620 countsByYear W20809636202021 @default.
• W2080963620 crossrefType "journal-article" @default.
• W2080963620 hasAuthorship W2080963620A5007449877 @default.
• W2080963620 hasAuthorship W2080963620A5012296345 @default.
• W2080963620 hasAuthorship W2080963620A5012408300 @default.
• W2080963620 hasAuthorship W2080963620A5013556625 @default.
• W2080963620 hasAuthorship W2080963620A5016011073 @default.
• W2080963620 hasAuthorship W2080963620A5059081727 @default.
• W2080963620 hasConcept C121608353 @default.
• W2080963620 hasConcept C126322002 @default.
• W2080963620 hasConcept C126894567 @default.
• W2080963620 hasConcept C141071460 @default.
• W2080963620 hasConcept C2776256026 @default.
• W2080963620 hasConcept C2780306776 @default.
• W2080963620 hasConcept C71924100 @default.
• W2080963620 hasConcept C90924648 @default.
• W2080963620 hasConceptScore W2080963620C121608353 @default.
• W2080963620 hasConceptScore W2080963620C126322002 @default.
• W2080963620 hasConceptScore W2080963620C126894567 @default.
• W2080963620 hasConceptScore W2080963620C141071460 @default.
• W2080963620 hasConceptScore W2080963620C2776256026 @default.
• W2080963620 hasConceptScore W2080963620C2780306776 @default.
• W2080963620 hasConceptScore W2080963620C71924100 @default.
• W2080963620 hasConceptScore W2080963620C90924648 @default.
• W2080963620 hasIssue "3" @default.
• W2080963620 hasLocation W20809636201 @default.
• W2080963620 hasLocation W20809636202 @default.
• W2080963620 hasOpenAccess W2080963620 @default.
• W2080963620 hasPrimaryLocation W20809636201 @default.
• W2080963620 hasRelatedWork W113810927 @default.
• W2080963620 hasRelatedWork W1586374228 @default.
• W2080963620 hasRelatedWork W2003938723 @default.
• W2080963620 hasRelatedWork W2047967234 @default.
• W2080963620 hasRelatedWork W2118496982 @default.
• W2080963620 hasRelatedWork W2364998975 @default.
• W2080963620 hasRelatedWork W2369162477 @default.
• W2080963620 hasRelatedWork W2439875401 @default.
• W2080963620 hasRelatedWork W4238867864 @default.
• W2080963620 hasRelatedWork W2525756941 @default.
• W2080963620 hasVolume "19" @default.
• W2080963620 isParatext "false" @default.
• W2080963620 isRetracted "false" @default.
• W2080963620 magId "2080963620" @default.
• W2080963620 workType "article" @default.